Impact of Covid-19 on Rhinovirus Epidemic

Rhinovirus Clinical Trial

— IPCoRV  

Official title:

Impact of Covid-19 Pandemic on the Epidemiology of Rhinovirus

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05348707
• Other study ID #: 502_2
• Status: Not yet recruiting
• Start date: May 2022
• Est. completion date: May 2023

Study information

• Verified date: February 2022
• Source: Hospices Civils de Lyon
• Contact: Dominique PLOIN, MD
• Phone: : 04 27 85 56 42
• Email: dominique.ploin[@]chu-lyon.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Rhinovirus (RV) has long been known as the main etiological agent of "common colds" among children and adults. Indeed, RV is involved in more than 50% of upper respiratory tract infections (URTIs), mostly characterized by nasal congestion, rhinorrhea, sore throat and cough. RV can also cause mild to severe lower respiratory tract infections (LRTIs) such as acute bronchiolitis, pneumonia and exacerbations of underlying chronic lung diseases. RV circulates worldwide, especially in temperate climate zones (i.e. many areas of the USA and Europe) and is responsible for annual outbreaks from early fall to the end of spring.

The covid-19 pandemic in 2020 seemed to interfere with the usual seasonal epidemics. For example, the winter Respiratory Syncytial Virus (RSV) epidemic in Lyon, France, was delayed for several months and reduced by half in terms of incidence of hospitalization cases. This can be explained by the widespread deployment of barrier gestures and social distancing measures, known as "non pharmacological interventions" (NPI).

However, the Covid-19 pandemic doesn't seem to have the same reducing impact on Rhinovirus epidemic. A better understanding of viral interactions and factors influencing RV epidemiology as well as the identification of populations at greater risk are required to improve preventive strategies and reduce the burden of Rhinovirus.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 400
• Est. completion date: May 2023
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 1 Year

Eligibility

Inclusion Criteria:

• - Child hospitalized at the " Hopital Femme Mere Enfant ", Lyon, France

• Positive rhinovirus-PCR

Exclusion Criteria:

• - parent's refusal to participate

Related Conditions & MeSH terms

• Rhinovirus

Intervention

Other:
• epidemiology
To review medical records to describe diagnosis and severity of the disease.
• epidemiology
To compare pre and per Covid-19 epidemics in terms of numbers of admissions and proportion of severe disease.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of pre Covid-19 pandemic.	Description of number of clinical picture cases for pre-SARS-CoV-2 pandemic year.	From one year before the SARS-CoV-2 pandemic until the beginning of the SARS-CoV-2 pandemic
Primary	Evolution of the number of children hospitalized for a Rhinovirus-infection in the period of per-Covid-19 pandemic.	Description of number of clinical picture cases for per-SARS-CoV-2 pandemic year.	From the beginning of the SARS-CoV-2 pandemic until one year latter